Head-to-head · WeighScore
Aurelius Health Group vs Rewinding RX
The verdict
Aurelius Health Group takes it — 60.8/100 to 59.5/100, but only just.
Aurelius Health Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aurelius Health Group is a telehealth platform built around compounded tirzepatide microdosing — a low-dose dual GIP/GLP-1 protocol rather than standard full-dose therapy — with optional NAD+, L-carnitine,… Rewinding RX is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aurelius Health Group | Rewinding RX |
|---|---|---|
| WeighScore | 60.8/100 | 59.5/100 |
| Grade | C | C |
| Scorecard rank | #311 | #340 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | $199/mo (microdose tier, compounded) | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #311 · C
Strengths
- Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
- LegitScript Certified
- Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
- Unusually candid about the limited evidence base for microdosing
Where it loses points
- The advertised $89 is a first-month new-patient rate; every month after it is $199
- This is a 1 mg microdose programme and nothing else — no labelled therapeutic dose is sold, so it is not an alternative to a full-dose prescription
- No state count is published, only 'most US states', confirmed at intake
- The site's own comparison table calls 2.4 mg/week the tirzepatide 'standard full dose'; 2.4 mg is the semaglutide maintenance dose, and tirzepatide is labelled 2.5-15 mg/week
- Compounded tirzepatide is not an FDA-approved finished product
Graded #340 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer — uncommon transparency
- MD-only physician network ('never a physician assistant or nurse')
- All-50-state coverage with physician state-licensing matching
- Corporate entity disclosed (Rewinding RX Ltd.)
Where it loses points
- Pricing not shown — fully gated behind sign-up
- Pharmacy partner not named (only generic 503A/503B references)
- Medical director / clinical leadership not disclosed
- Governing law, arbitration venue, and corporate address not disclosed
- Tirzepatide not listed on the homepage (semaglutide only confirmed)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.